Vaccination with p53-peptide-pulsed dendritic cells, of patients with advanced breast cancer: report from a phase I study.
about
Immunologic aspect of ovarian cancer and p53 as tumor antigen.Breast cancer vaccines: a clinical reality or fairy tale?Strategies and challenges in eliciting immunity to melanoma.Ovarian cancer immunotherapy: opportunities, progresses and challengesRelationship of p53 overexpression on cancers and recognition by anti-p53 T cell receptor-transduced T cellsPotential target antigens for a universal vaccine in epithelial ovarian cancer.Recognition of fresh human tumor by human peripheral blood lymphocytes transduced with a bicistronic retroviral vector encoding a murine anti-p53 TCR.Immunological and clinical effects of vaccines targeting p53-overexpressing malignancies.Apoptosis in cancer: from pathogenesis to treatment.CTLA-4 blockade during dendritic cell based booster vaccination influences dendritic cell survival and CTL expansion.Supernatural T cells: genetic modification of T cells for cancer therapy.Towards a therapeutic breast cancer vaccine: the next steps.Trial watch: Dendritic cell-based interventions for cancer therapyDendritic cell immunotherapy for breast cancer.Breast cancer immunobiology driving immunotherapy: vaccines and immune checkpoint blockade.Cancer vaccines in old age.Vaccine immunotherapy in breast cancer treatment: promising, but still early.Breast cancer stem cells: implications for therapy of breast cancer.Toward the development of multi-epitope p53 cancer vaccines: an in vitro assessment of CD8(+) T cell responses to HLA class I-restricted wild-type sequence p53 peptides.A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patientsDevelopment of multi-epitope vaccines targeting wild-type sequence p53 peptides.Breast cancer vaccines: ongoing National Cancer Institute-registered clinical trials.Vaccination for the prevention and treatment of breast cancer with special focus on Her-2/neu peptide vaccines.Peptide-based vaccination and induction of CD8+ T-cell responses against tumor antigens in breast cancer.Dendritic cells pulsed with alpha-fetoprotein and mutant P53 fused gene induce bi-targeted cytotoxic T lymphocyte response against hepatic carcinoma.Murine mammary adenocarcinoma cells transfected with p53 and/or Flt3L induce antitumor immune responses.mRNA-transfected dendritic cell vaccine in combination with metronomic cyclophosphamide as treatment for patients with advanced malignant melanoma.Addition of TAT protein transduction domain and GrpE to human p53 provides soluble fusion proteins that can be transduced into dendritic cells and elicit p53-specific T-cell responses in HLA-A*0201 transgenic mice.Phenotypic and functional characterization of clinical grade dendritic cells generated from patients with advanced breast cancer for therapeutic vaccination.The mutational status of p53 can influence its recognition by human T-cells.Breast cancer vaccination comes to age: impacts of bioinformaticsSeromic profiling of colorectal cancer patients with novel glycopeptide microarrayImmunopeptidomic Profiling of HLA-A2-Positive Triple Negative Breast Cancer Identifies Potential Immunotherapy Target AntigensDendritic Cell-Based Immunotherapy
P2860
Q24814703-CD8E57B5-0409-486D-9DB8-8AE3ABA18897Q30351838-0C05736F-EC8E-4578-A249-F9D5F88AAB7CQ30435893-979AE588-D7C3-414D-B418-60F2272CD18DQ33702218-31EA145A-6416-4DA0-9915-B3479CB5C1CEQ33927506-635941D1-4526-4757-94BF-9BE545A4942EQ34159451-00DB3C83-B13A-4453-A2D6-268BB7541AD6Q34657661-6F9F3437-4C08-4351-AB27-5C1CAFA3F5A0Q34898280-5AA8FF27-2D16-4215-B549-C9DF21069DE5Q35397889-D883682B-E5CD-45A7-9B01-EB67A6FA422CQ35945339-079E665B-48E4-4DAD-9DAD-CD385B7698A2Q36328805-BEA4A6BF-945E-443D-8163-43F4B913FDAFQ36350565-C4C7E67B-F38E-4BD8-A40B-CD0C8C72A522Q36388529-3A617ED1-6F75-4779-801E-61FA7FBC3560Q36480998-2FF08F2B-2325-4A4F-BEDC-05AC70697BE2Q36653524-84A2F0BA-E333-4181-AAC0-DEA0067DCE65Q36695917-B0632586-D019-4E79-A69C-4C6E649A14C3Q36950477-F2BA1846-81B6-48B8-8A14-599CEC4673F0Q36955061-458201B5-DC35-4FF7-B023-59B49301CE1EQ36973865-F90E59EF-8D28-4AA6-AE54-28CAEC577A66Q37002959-184DAC77-8C61-403B-B0AE-0455A1583D87Q37259621-318E9E1A-47DA-465F-A9BF-0B906206A17AQ37892580-6E09E52B-1D95-418A-9970-E4EB0793FDD6Q38076053-222B01F7-835F-4DDE-A102-4EE8A0142856Q38293525-827AA4C5-79BD-451D-AB16-AC8BDCD04114Q39990751-013FDDE0-A38A-4D60-B735-6F0E3D95EE71Q40464391-37887113-D611-4CBC-8510-711062BCC1C1Q41297982-0C1CA02A-836E-4530-A9CF-8842F6001BF7Q44960269-1021FC8C-0560-4AAE-845F-E8DDF041B954Q45245826-0639C1C5-16BB-4400-B0B5-E2A8B0A5755BQ50999703-6E2121AF-753C-445F-A271-2112EDA1A807Q57114951-FF85CA80-A0D9-451A-9754-57DE45793FE7Q57195324-1E69F28E-9398-48BF-9B57-7243C5475514Q58214193-DA1718BA-179B-499C-84E5-171DB819E398Q58409682-6384A852-2A78-4907-86D0-1502155FF1AD
P2860
Vaccination with p53-peptide-pulsed dendritic cells, of patients with advanced breast cancer: report from a phase I study.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Vaccination with p53-peptide-p ...... : report from a phase I study.
@en
Vaccination with p53-peptide-p ...... : report from a phase I study.
@nl
type
label
Vaccination with p53-peptide-p ...... : report from a phase I study.
@en
Vaccination with p53-peptide-p ...... : report from a phase I study.
@nl
prefLabel
Vaccination with p53-peptide-p ...... : report from a phase I study.
@en
Vaccination with p53-peptide-p ...... : report from a phase I study.
@nl
P2093
P50
P1476
Vaccination with p53-peptide-p ...... : report from a phase I study.
@en
P2093
Claus Kamby
Dorte Nielsen
Eva Gaarsdal
Kirsten Nikolajsen
Mogens H Claesson
P2888
P304
P356
10.1007/S00262-003-0493-5
P577
2004-02-25T00:00:00Z